Navin Molecular, an Indian-based CDMO that is part of Navin Fluorine, has announced plans to build $35 million, 9,000 m2 multi-purpose GMP plant at Dewas. This is due to be completed in Q2 225. The facility will add 200 m3 of capacity, taking the total at Dewas to 420. It will support existing commercial-scale projects, as well as meeting future demands, the company said.
India’s Navin Fluorine International has officially launched its CDMO division under the name Navin Molecular. The company has been providing chemistry services since 2010 and is launching the band “to showcase the broad platform that Navin Molecular can offer” in terms of geographical diversity and expertise in a range of complex chemistries.
Pharmaceutical CDMO Piramal Pharma Solutions (PPS) is to invest about $32 million to expand its former Ash Stevens API manufacturing site at Riverview, Michigan. This will add 2,300 m2 of space, including 780 m2 of production space.
